October 2019
Price: £95 PLUS VAT
Format: DOWNLOADABLE PDF
This conference was an opportunity to discuss cancer care in England - looking at access to treatment, improving diagnosis and implementing new policy initiatives.
It came as Rapid Diagnostic Centres are rolled out across England this year and a new faster diagnosis standard is set to be introduced from 2020. Sessions considered the priorities for implementing the new initiatives.
Following the announcement of the Accelerating Detection of Disease programme, which commits £79m of government investment for research into early diagnosis for diseases including cancer, delegates assessed how to support innovation in diagnosis and ensure the uptake of new technologies.
Attendees also discussed the next steps for improving cancer screening in England - following the publication of the interim report for the review of national cancer screening programmes in England.
Further sessions considered the future role of genomics in cancer care - looking at the progress of the Genomic Medicine Service, the personalisation of cancer treatment and overcoming challenges regarding patient data.
Delegates also discussed improving the quality of cancer care, as access to personalised care is due to be offered where appropriate to every person diagnosed with cancer by 2021, as well as the development of the cancer care workforce - including the expansion of multidisciplinary teams.
Following the Government’s announcement that the use of Artificial Intelligence and data to improve the diagnosis and treatment of chronic diseases will be included as one of the country’s Grand Challenge missions, this seminar provided an opportunity to consider early progress as well as identifying other opportunities to accelerate innovation in cancer treatment and for collaborative research.
It also included discussion on the development of cancer drugs - looking at long-term investment, collaborative research and improving access to medicine.
Further sessions looked at the progress of the Cancer Drugs Fund, the impact of evidence compiled through data collection and the opportunities to increase managed access to innovative cancer treatments - including CAR T-cell therapy for adults with lymphoma, which was made accessible through the Cancer Drugs Fund in early 2019.
